青松股份(300132.SZ):諾斯貝爾取得實用新型專利及外觀設計專利
格隆匯 3 月 2日丨青松股份(300132.SZ)公佈,公司全資子公司諾斯貝爾化粧品股份有限公司(“諾斯貝爾”)近日收到了國家知識產權局頒發的《實用新型專利證書》及《外觀設計專利證書》,實用新型專利為一種非接觸式面膜布厚度檢測裝置、一種卡板自動清洗機;外觀設計專利為膏霜瓶(心形)。
上述專利的取得不會對諾斯貝爾目前生產經營情況產生重大影響,但有利於諾斯貝爾進一步完善知識產權保護體系,形成持續創新機制,提升諾斯貝爾的核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.